ArticleClinical oral investigations2025
Annexin A1 levels in polycystic ovary syndrome: impact of professional mechanical plaque removal.
Article in Clinical oral investigations, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Periodontal disease and endocrine imbalance: a molecular pathways perspective.Frontiers in dental medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThis study aimed to investigate the local inflammatory profile in women with polycystic ovary syndrome (PCOS) by assessing interleukin (IL)-6, IL-10, and annexin A1 (ANXA1) levels in saliva and gingival crevicular fluid (GCF), and to compare the clinical and biochemical responses to proffessional mechanical plaque removal (PMPR) between women with PCOS and systemically healthy individuals.
methodsEighty women were allocated into four groups: (1) PCOS-healthy periodontium (PCOSH), (2) PCOS-gingivitis (PCOSG), (3) systemically healthy-gingivitis (SG), (4) systemically and periodontally healthy (SH). Clinical periodontal parameters and saliva/GCF samples were collected at baseline and 6 weeks after PMPR. IL-6, IL-10, and ANXA1 levels were measured by ELISA. Data were analyzed using one-way ANOVA, Kruskal-Wallis tests, and multiple linear regression.
resultsBoth gingivitis groups showed comparable clinical improvements and significant reductions in salivary IL-6 levels and the IL-6/IL-10 ratio following PMPR, independent of PCOS status. Notably, GCF ANXA1 levels increased in PCOSG but decreased in SG. In the PCOSG group, baseline levels of estradiol and follicle-stimulating hormone were significant predictors of changes in GCF ANXA1, as indicated by multiple regression analysis.
conclusionPMPR may lead to similar clinical and local biochemical outcomes in patients with gingivitis, regardless of PCOS status. ANXA1 may have a specific role in modulating gingival inflammation in women with PCOS. CLINICAL RELEVANCE: This study highlights the importance of managing gingivitis in women with PCOS, suggesting that periodontal treatment may result in comparable improvements. Additionally, the findings suggest a potential modulatory role for ANXA1 in the periodontal inflammatory response associated with PCOS.
Indexed as
Identifiers
40789814What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.